Literature DB >> 20050854

P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice.

Pieter-Jan D F Guns1, Jan Hendrickx, Tim Van Assche, Paul Fransen, Hidde Bult.   

Abstract

BACKGROUND AND
PURPOSE: P2Y nucleotide receptors are involved in the regulation of vascular tone, smooth muscle cell (SMC) proliferation and inflammatory responses. The present study investigated whether they are involved in atherosclerosis. EXPERIMENTAL APPROACH: mRNA of P2Y receptors was quantified (RT-PCR) in atherosclerotic and plaque-free aorta segments of apolipoprotein E-deficient (apoE(-/-)) mice. Macrophage activation was assessed in J774 macrophages, and effects of non-selective purinoceptor antagonists on atherosclerosis were evaluated in cholesterol-fed apoE(-/-) mice. KEY
RESULTS: P2Y(6) receptor mRNA was consistently elevated in segments with atherosclerosis, whereas P2Y(2) receptor expression remained unchanged. Expression of P2Y(1) or P2Y(4) receptor mRNA was low or undetectable, and not influenced by atherosclerosis. P2Y(6) mRNA expression was higher in cultured J774 macrophages than in cultured aortic SMCs. Furthermore, immunohistochemical staining of plaques demonstrated P2Y(6)-positive macrophages, but few SMCs, suggesting that macrophage recruitment accounted for the increase in P2Y(6) receptor mRNA during atherosclerosis. In contrast to ATP, the P2Y(6)-selective agonist UDP increased mRNA expression and activity of inducible nitric oxide synthase and interleukin-6 in J774 macrophages; this effect was blocked by suramin (100-300 microM) or pyridoxal-phosphate-6-azophenyl-2'-4'-disulphonic acid (PPADS, 10-30 microM). Finally, 4-week treatment of cholesterol-fed apoE(-/-) mice with suramin or PPADS (50 and 25 mg.kg(-1).day(-1) respectively) reduced plaque size, without changing plaque composition (relative SMC and macrophage content) or cell replication. CONCLUSIONS AND IMPLICATIONS: These results suggest involvement of nucleotide receptors, particularly P2Y(6) receptors, during atherosclerosis, and warrant further research with selective purinoceptor antagonists or P2Y(6) receptor-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20050854      PMCID: PMC2825354          DOI: 10.1111/j.1476-5381.2009.00497.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  The Role of P2Y Receptors in the Control of Blood Pressure.

Authors:  Markus Van Der Giet; Gunter Giebing; Markus Tolle; Sven Schmidt
Journal:  Drug News Perspect       Date:  2002-12

2.  Cloning, up-regulation, and mitogenic role of porcine P2Y2 receptor in coronary artery smooth muscle cells.

Authors:  Jianzhong Shen; Cheikh I Seye; Meifang Wang; Gary A Weisman; Peter A Wilden; Michael Sturek
Journal:  Mol Pharmacol       Date:  2004-07-27       Impact factor: 4.436

3.  Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta.

Authors:  Pieter-Jan D F Guns; András Korda; Herta M Crauwels; Tim Van Assche; Bernard Robaye; Jean-Marie Boeynaems; Hidde Bult
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

4.  Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.

Authors:  Jacek Jawien; Gabor Csanyi; Mariusz Gajda; Lukasz Mateuszuk; Magdalena Lomnicka; Ryszard Korbut; Stefan Chlopicki
Journal:  Eur J Pharmacol       Date:  2006-11-15       Impact factor: 4.432

5.  Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin.

Authors:  Y Hu; Y Zou; H Dietrich; G Wick; Q Xu
Journal:  Circulation       Date:  1999-08-24       Impact factor: 29.690

6.  Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage.

Authors:  E Lutgens; M Daemen; M Kockx; P Doevendans; M Hofker; L Havekes; H Wellens; E D de Muinck
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

7.  Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors.

Authors:  Béatrice Hechler; Monique Freund; Catherine Ravanat; Stéphanie Magnenat; Jean-Pierre Cazenave; Christian Gachet
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

8.  Effect of non-steroidal anti-inflammatory drugs on amyloid-beta formation and macrophage activation after platelet phagocytosis.

Authors:  Dominique M Jans; Wim Martinet; Marianne Fillet; Mark M Kockx; Marie-Paule Merville; Hidde Bult; Arnold G Herman; Guido R Y De Meyer
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

9.  Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox.

Authors:  Anna Rubartelli; Michael T Lotze
Journal:  Trends Immunol       Date:  2007-09-12       Impact factor: 16.687

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  12 in total

1.  Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2011-09-14       Impact factor: 7.658

Review 2.  P2Y nucleotide receptors: promise of therapeutic applications.

Authors:  Kenneth A Jacobson; Jean-Marie Boeynaems
Journal:  Drug Discov Today       Date:  2010-06-02       Impact factor: 7.851

3.  Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y6 Receptor Agonists.

Authors:  Kiran S Toti; Shanu Jain; Antonella Ciancetta; Ramachandran Balasubramanian; Saibal Chakraborty; Ryan Surujdin; Zhen-Dan Shi; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-09-06       Impact factor: 3.597

4.  AMP-activated protein kinase as regulator of P2Y(6) receptor-induced insulin secretion in mouse pancreatic β-cells.

Authors:  Ramachandran Balasubramanian; Hiroshi Maruoka; P Suresh Jayasekara; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2013-01-17       Impact factor: 5.858

5.  Purinergic P2Y2 Receptor Control of Tissue Factor Transcription in Human Coronary Artery Endothelial Cells: NEW AP-1 TRANSCRIPTION FACTOR SITE AND NEGATIVE REGULATOR.

Authors:  Yiwei Liu; Lingxin Zhang; Chuan Wang; Shama Roy; Jianzhong Shen
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.157

6.  Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a novel nucleotide phosphodiesterase regulated by cholesterol in human macrophages.

Authors:  Mathew Traini; Carmel M Quinn; Cecilia Sandoval; Erik Johansson; Kate Schroder; Maaike Kockx; Peter J Meikle; Wendy Jessup; Leonard Kritharides
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

Review 7.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

8.  Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists.

Authors:  Ramachandran Balasubramanian; Bernard Robaye; Jean-Marie Boeynaems; Kenneth A Jacobson
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

Review 9.  The role of nucleotides and purinergic signaling in apoptotic cell clearance - implications for chronic inflammatory diseases.

Authors:  Jin Chen; Yi Zhao; Yi Liu
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

10.  P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development.

Authors:  Ricardo A Garcia; Mujing Yan; Debra Search; Rongan Zhang; Nancy L Carson; Carol S Ryan; Constance Smith-Monroy; Joanna Zheng; Jian Chen; Yan Kong; Huaping Tang; Samuel E Hellings; Judith Wardwell-Swanson; Joseph E Dinchuk; George C Psaltis; David A Gordon; Peter W Glunz; Peter S Gargalovic
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.